Table 2.
Overview on the distribution of individually assessed parameters in patients with S. aureus or E. coli infections
| Parameter |
S. aureus n = 1040 |
E. coli n = 975 |
Overall n = 2015 |
|---|---|---|---|
| Death n (%) | 128 (12.4%) | 91 (9.3%) | 219 (10.9%) |
| Gender | |||
| Male | 648 (62.3%) | 423 (43.4%) | 1071 (53.2%) |
| Female | 392 (37.7%) | 552 (56.6%) | 944 (46.9%) |
| Patient group | |||
| Systemic infection | 405 (38.9%) | 353 (36.2%) | 758 (37.6%) |
| Superficial infection | 557 (53.6%) | 482 (49.4%) | 1039 (51.6%) |
| Combined superficial and systemic infection | 78 (5.5%) | 140 (14.4%) | 218 (10.8%) |
| Sample materials | |||
| Ascites | 3 (0.3%) | 10 (1.0%) | 13 (0.7%) |
| Biopsies and invasive foreign material | 47 (4.5%) | 428 (43.9%) | 475 (23.6%) |
| Blood cultures | 234 (22.5%) | 245 (25.1%) | 479 (23.8%) |
| Bronchial lavage | 17 (1.6%) | 19 (2.0%) | 36 (1.8%) |
| Respiratory secretions | 127 (12.2%) | 37 (3.8%) | 164 (8.1%) |
| Aspirates | 14 (1.4%) | 35 (3.6%) | 49 (2.4%) |
| Abscess materials | 70 (6.7%) | 73 (7.5%) | 143 (7.1%) |
| Wound swabs | 501 (48.2%) | 27 (2.8%) | 528 (26.2%) |
| Urine | 27 (2.6%) | 101 (10.4%) | 128 (6.4%) |
| Main diagnoses | |||
| Endocrinology/metabolic disorders | 16 (1.5%) | 4 (0.4%) | 20 (1.0%) |
| Gastroenterology | 56 (5.4%) | 175 (17.8%) | 231 (11.5%) |
| Cardiovascular disease | 99 (9.5%) | 82 (8.4%) | 181 (9.0%) |
| Local infection | 333 (32.0%) | 35 (3.6%) | 368 (18.3%) |
| Systemic infection | 103 (9.9%) | 183 (18.8%) | 286 (14.2%) |
| Rheumatology and neoplasia | 108 (10.4%) | 131 (13.4%) | 239 (11.7%) |
| Neurological disorder | 116 (11.2%) | 24 (2.5%) | 140 (7.0%) |
| Orthopedics/Traumatology | 79 (7.6%) | 24 (2.4%) | 103 (5.1%) |
| Pulmonary disease | 60 (5.8%) | 80 (8.2%) | 140 (7.0%) |
| Other diseases | 37 (3.6%) | 50 (5.1%) | 87 (4.3%) |
| Urologic disease | 33 (3.2%) | 187 (19.2%) | 220 (10.9%) |
| Ward | |||
| Surgical | 422 (40.6%) | 394 (40.4%) | 816 (40.5%) |
| Medical | 618 (59.4%) | 581 (59.6%) | 1199 (59.5%) |
| Previous antibiotic therapy | |||
| Not documented | 594 (57.1%) | 665 (68.2%) | 1259 (62.5%) |
| Documented | 446 (42.9%) | 310 (31.8%) | 756 (37.5%) |
| Ampicillin | |||
| Susceptible | 40 (37.7%) | 462 (47.7%) | 502 (46.7%) |
| Resistant | 66 (62.3%) | 507 (52.3%) | 573 (53.3%) |
| Levofloxacin | |||
| Susceptible | 841 (85.8%) | n.a. | 841 (85.8%) |
| Resistant | 139 (14.2%) | n.a. | 139 (14.2%) |
| Norfloxacin | |||
| Susceptible | 220 (85.9%) | n.a. | 220 (85.9%) |
| Resistant | 36 (14.1%) | n.a. | 36 (14.1%) |
| Ciprofloxacin | |||
| Susceptible | 221 (86.0%) | 728 (75.2%) | 949 (77.5%) |
| Resistant | 36 (14.0%) | 240 (24.8%) | 276 (22.5%) |
| Moxifloxacin | |||
| Susceptible | 860 (87.8%) | n.a. | 860 (87.8%) |
| Resistant | 119 (12.2%) | n.a. | 119 (12.2%) |
| Erythromycin | |||
| Susceptible | 880 (89.8%) | n.a. | 880 (89.8%) |
| Resistant | 100 (10.2%) | n.a. | 100 (10.2%) |
| Clindamycin | |||
| Susceptible | 885 (90.3%) | n.a. | 885 (90.3%) |
| Resistant | 95 (9.7%) | n.a. | 95 (9.7%) |
| Quinupristin | |||
| Susceptible | 256 (100%) | n.a. | 256 (100%) |
| Resistant | 0 | n.a. | 0 |
| Gentamicin | |||
| Susceptible | 957 (97.8%) | 915 (94.3%) | 1872 (96.1%) |
| Resistant | 22 (2.3%) | 55 (5.7%) | 77 (4.0%) |
| Tetracycline | |||
| Susceptible | 905 (92.4%) | 390 (61.2%) | 1295 (80.1%) |
| Resistant | 74 (7.6%) | 247 (38.8%) | 321 (19.9%) |
| Tobramycin | |||
| Susceptible | 822 (97.4%) | n.a. | 822 (97.4%) |
| Resistant | 22 (2.6%) | n.a. | 22 (2.6%) |
| Tigecycline | |||
| Susceptible | 722 (100%) | 426 (100%) | 1148 (100%) |
| Resistant | 0 | 0 | 0 |
| Co-trimoxazole | |||
| Susceptible | 972 (99.3%) | 686 (70.4%) | 1658 (84.9%) |
| Resistant | 7 (0.7%) | 289 (29.6%) | 296 (15.2%) |
| Fosfomycin | |||
| Susceptible | 972 (99.4%) | 334 (99.4%) | 1306 (99.4%) |
| Resistant | 6 (0.6%) | 2 (0.6%) | 8 (0.6%) |
| Fusidic acid | |||
| Susceptible | 950 (97.5%) | n.a. | 950 (97.5%) |
| Resistant | 24 (2.5%) | n.a. | 24 (2.5%) |
| Rifampicin | |||
| Susceptible | 976 (99.7%) | n.a. | 976 (99.7%) |
| Resistant | 3 (0.3%) | n.a. | 3 (0.3%) |
| Oxacillin | |||
| Susceptible | 1035 (100%) | n.a. | 1035 (100%) |
| Resistant | 0 | n.a. | 0 |
| Ampicillin–Sulbactam | |||
| Susceptible | 948 (100%) | 580 (65.2%) | 1528 (83.1%) |
| Resistant | 0 | 310 (84.8%) | 310 (16.9%) |
| Cefoxitin | |||
| Susceptible | 964 (100%) | n.a. | 964 (100%) |
| Resistant | 0 | n.a. | 0 |
| Cefuroxime | |||
| Susceptible | 948 (100%) | n.a. | 948 (100%) |
| Resistant | 0 | n.a. | 0 |
| Imipenem | |||
| Susceptible | 948 (100%) | 974 (100%) | 1922 (100%) |
| Resistant | 0 | 0 | 0 |
| Teicoplanin | |||
| Susceptible | 978 (100%) | n.a. | 978 (100%) |
| Resistant | 0 | n.a. | 0 |
| Vancomycin | |||
| Susceptible | 978 (100%) | n.a. | 978 (100%) |
| Resistant | 0 | n.a. | 0 |
| Linezolid | |||
| Susceptible | 980 (100%) | n.a. | 980 (100%) |
| Resistant | 0 | n.a. | 0 |
| Daptomycin | |||
| Susceptible | 137 (99.3%) | n.a. | 137 (99.3%) |
| Resistant | 1 (0.7%) | n.a. | 1 (0.7%) |
| Mupirocin | |||
| Susceptible | 963 (99.8%) | n.a. | 963 (99.8%) |
| Resistant | 2 (0.2%) | n.a. | 2 (0.2%) |
| Third-generation cephalosporins | |||
| Susceptible | n.a. | 835 (88.6%) | 835 (88.6%) |
| Resistant | n.a. | 108 (11.5%) | 108 (11.5%) |
| Fourth-generation cephalosporins | |||
| Susceptible | n.a. | 901 (92.6%) | 901 (92.6%) |
| Resistant | n.a. | 72 (7.4%) | 72 (7.4%) |
| Piperacillin–Tazobactam | |||
| Susceptible | n.a. | 747 (85.4%) | 747 (85.4%) |
| Resistant | n.a. | 128 (14.6%) | 128 (14.6%) |
| Days in hospital | 1440 | 974 | 2014 |
| (available for (n)) | |||
| Mean (SD) | 19.6 (19.2) | 15.3 (16.3) | 17.6 (18.0) |
| Median | 14.0 | 10.0 | 12.0 |
| Days to sample | 1040 | 975 | 2015 |
| acquisition | |||
| (available for (n)) | |||
| Mean (SD) | 4.7 (10.4) | 3.8 (7.5) | 4.3 (9.1) |
| Median | 1.0 | 1.0 | 1.0 |
| Age (available for (n)) | 1040 | 975 | 2015 |
| Mean (SD) | 58.3 (22.0) | 69.3 (15.1) | 63.6 (19.7) |
| Median | 63.0 | 72.0 | 69.0 |
| CRP (available for (n)) | 1009 | 899 | 1908 |
| Mean (SD) | 1.9(1.1) | 2.1 (1.0) | 2.0 (1.0) |
| Median | 2.0 | 2.0 | 2.0 |
| PCT (available for (n)) | 242 | 157 | 399 |
| Mean (SD) | 1.2 (0.5) | 1.3 (0.2) | 1.3 (0.5) |
| Median | 1.0 | 1.0 | 1.0 |
| Leukocytes | 998 | 975 | 1973 |
| (available for (n)) | |||
| Mean (SD) | 2.5 (0.6) | 2.5 (0.6) | 2.5 (0.6) |
| Median | 3.0 | 3.0 | 3.0 |